A Study of LY4006895 for Alzheimer's Disease
This study is testing a drug called LY4006895. Its main goal is to see how safe LY4006895 is and if people can tolerate it well. There are two parts to the study. Part A will give a single dose of LY40068995 to healthy volunteers. Part B will give multiple doses of LY4006895 to people with early Alzheimer's disease (AD). You could be between 45 and 85 years old to join. Researchers will also take blood samples to understand how the body uses and gets rid of LY4006895. The study will look at any side effects that happen during the study period, which can be up to 61 weeks.
- Study design
- This is an interventional study with a planned enrollment of 128 participants. It has two parts: one for healthy participants and one for participants with early symptomatic Alzheimer's Disease.
- What's involved
- Participants will receive LY4006895 or a placebo intravenously (through a vein). Blood tests will be performed. Part A lasts about 29 weeks, and Part B lasts about 61 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for adverse events from baseline up to study completion, which is up to 61 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06657768
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
Recruiting
PHASE1Ages 45–85InterventionalBasic scienceEli Lilly and Company
~128 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:LY4006895Placebo
At a glance
Recruiting sites
6 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Discontinuations due to Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration
Measured over Baseline to Study Completion (Up to 61 Weeks)
Conditions
Where it's being run
13 sites across 7 statesFlorida5
Georgia2
Japan2
California1
Michigan1
New Jersey1
North Carolina1
Study leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Are overtly healthy as determined by medical evaluation. Rescreening is not allowed in this study
Have early symptomatic AD, as defined by:
Gradual and progressive change in memory function for at least 6 months, as reported by the participant or informant
A Mini-Mental State Exam (MMSE) score of 18 to 30 at screening
A Clinical Dementia Rating (CDR) global score of 0.5 to 1.0 (inclusive), with a memory box score greater than or equal to 0.5 at screening
Have up to 2 reliable study partners who are in frequent contact with the participant (defined as at least 10 hours per week), one of whom at any one occasion: will accompany the participant to the study visits, will be available by telephone at designated times, and will provide a separate written informed consent to participate
Exclusion
Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (MAD: other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the participant's ability to complete the study; or has a life expectancy of less than 24 months
Have screening hemoglobin (Hb) less than 12 grams per deciliter (g/dL) or evidence of iron-deficiency (ferritin less than 30 nanograms per milliliter (ng/mL), or presence/history of hemoglobinopathy
Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide
Regularly use known drugs of abuse and/or show positive findings on urinary drug screening that cannot be explained by regular concomitant medications
Have previous exposure to any anti-tau therapy
Are pregnant or intend to become pregnant or to breastfeed during the study
Have a current exposure to an amyloid targeted therapy. Prior exposure to amyloid targeted therapies greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor. A listing of amyloid targeted therapies will be provided
Have a sensitivity to florataucipir 18F
Have contraindication to magnetic resonance imaging (MRI) including claustrophobia or the presence of contraindicated metal (ferrogmagnetic) implants/cardiac pacemaker
What this trial measures
- Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Discontinuations due to Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationBaseline to Study Completion (Up to 61 Weeks)
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module